ReviewMolecular psychiatry2026
Attention deficit hyperactivity disorder: transition to psychotic disorders.
Review in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well recognized that Attention-deficit/hyperactivity disorder (ADHD) is associated with heightened risk for common psychiatric disorders; early identification and treatment of ADHD may help reduce some of this risk. However, the substantially increased risk of bipolar disorder, psychosis, and schizophrenia (hereafter psychotic disorders) is often overlooked (odds ratios 4.7-8.9). Given how common ADHD is, there is growing pressure for greater involvement of primary care services, especially for less complex forms of ADHD. However, those at highest risk for transition to a psychotic disorder need to be prioritised for secondary care follow up. Currently it is unknown how to stratify ADHD according to risk or indeed why only some develop a psychotic disorder. This perspective examines key hypotheses that may explain why transition occurs only in a subset of individuals. One hypothesis is that features suggestive of ADHD may represent early manifestations of psychotic disorders, although direct support for this is limited. The potential role of ADHD treatment is also considered; current data indicate that therapeutic use of methylphenidate is not associated with increased risk of psychotic disorders, while uncertainty remains for amphetamines. The possible mediating roles of ADHD-evoked environmental exposures are discussed, but evidence for mediation is lacking. We also consider the evidence that ADHD and psychotic disorders result from shared underlying neurodevelopmental processes. We highlight key clinical implications for screening and monitoring individuals with ADHD for psychotic disorders and consider what factors may help in weighting risk. Finally, we identify important evidence gaps for future research.
Identifiers
42875515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.